416 related articles for article (PubMed ID: 25986879)
1. Meningococcal vaccines: Current state and future outlook.
Leca M; Bornet C; Montana M; Curti C; Vanelle P
Pathol Biol (Paris); 2015 Jun; 63(3):144-51. PubMed ID: 25986879
[TBL] [Abstract][Full Text] [Related]
2. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
[TBL] [Abstract][Full Text] [Related]
3. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
Bai X; Borrow R
Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
[TBL] [Abstract][Full Text] [Related]
4. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
Esposito S; Principi N
Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
[TBL] [Abstract][Full Text] [Related]
5. Evolving meningococcal immunization strategies.
Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
[TBL] [Abstract][Full Text] [Related]
6. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
[TBL] [Abstract][Full Text] [Related]
7. Meningococcal disease: a review on available vaccines and vaccines in development.
Bröker M; Fantoni S
Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
[TBL] [Abstract][Full Text] [Related]
8. Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 March 2005.
Alonso JM; Gilmet G; Rouzic EM; Nassif X; Plotkin SA; Ramsay M; Siegrist CA; Stephens DS; Teyssou R; Vogel U
Vaccine; 2007 May; 25(21):4125-9. PubMed ID: 17449149
[TBL] [Abstract][Full Text] [Related]
9. Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.
Mowlaboccus S; Perkins TT; Smith H; Sloots T; Tozer S; Prempeh LJ; Tay CY; Peters F; Speers D; Keil AD; Kahler CM
PLoS One; 2016; 11(6):e0158315. PubMed ID: 27355628
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
Watson PS; Turner DP
Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for prevention of group B meningococcal disease: Not your father's vaccines.
Harrison LH
Vaccine; 2015 Nov; 33 Suppl 4():D32-8. PubMed ID: 26116255
[TBL] [Abstract][Full Text] [Related]
12. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
Andrews SM; Pollard AJ
Lancet Infect Dis; 2014 May; 14(5):426-34. PubMed ID: 24679664
[TBL] [Abstract][Full Text] [Related]
13. Neisseria meningitidis B vaccines.
Panatto D; Amicizia D; Lai PL; Gasparini R
Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
[TBL] [Abstract][Full Text] [Related]
14. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
16. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
Martin NG; Snape MD
Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
[TBL] [Abstract][Full Text] [Related]
17. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.
Brehony C; Rodrigues CMC; Borrow R; Smith A; Cunney R; Moxon ER; Maiden MCJ
Vaccine; 2016 Sep; 34(39):4690-4697. PubMed ID: 27521232
[TBL] [Abstract][Full Text] [Related]
18. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
Dull PM; McIntosh ED
Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
Nolan T; O'Ryan M; Wassil J; Abitbol V; Dull P
Vaccine; 2015 Aug; 33(36):4437-45. PubMed ID: 26187261
[TBL] [Abstract][Full Text] [Related]
20. Bexsero® chronicle.
Vernikos G; Medini D
Pathog Glob Health; 2014 Oct; 108(7):305-16. PubMed ID: 25417906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
